The Leader in Neurological Research and Clinical Studies.

Past Studies

Our neurologists have successfully completed over 500 clinical research trials. Their work has contributed to medical advancements in the neurological community and has lead to discovering cutting-edge effective treatments for their patients.

A complete list of research studies as well as a CV for each doctor is available upon request.  Please reach out to a research coordinator for more information.

Thomas Banas, MD

Past Clinical Trials & Research

2019:    UCB Biopharma SPRL – A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy.   Sub-Investigator

2018:   Acadia Pharmaceuticals ACP-NIS-001 – An Observational Study on the Management of Parkinson’s Disease Psychosis in Actual Practice. Primary Investigator

2018:   F. Hoffmann- LaRoche – A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer’s Disease.  Sub-Investigator.

2018:   Alexion EC-NMO-302 – A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub Investigator.

2015:   Alexion EC-NMO-301 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub Investigator.

2015:  Biogen 101MS413 – A Phase IV Multicenter, Open-Label study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera (delayed-release dimethyl fumarate) treatment in MS patients. Sub-Investigator

2014:   Biogen 101MS409 – A Phase IIII Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis. Sub Investigator.

2013:   Sanofi Aventis LPS13567 – A Prospective, Single-Arm, Clinical-Setting, Study to Describe Efficacy, Tolerability and Convenience of AUBAGIO Treatment Using Patient Reported Outcomes in Relapsing Multiple Sclerosis Patients.

2013:   Teva LAQ MS 305 – A multinational, multicenter, randomized, double blind, parallel Group placebo controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquiniod in subjects with R.elapsing Remitting Multiple Sclerosis

2011:   Pfizer, Inc.: A0081242-A phase 3B multicenter, double-blind, randomized withdrawal efficacy and safety study of Pregabalin in the treatment of patients with inadequately treated painful diabetic peripheral neuropathy, Principle Investigator. 

2010:   Biogen Idec:101MS325- A multicenter, randomized, rater-blind, parallel-group, active controlled study to evaluate the benefits of switching therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in subjects with relapsing remitting multiple sclerosis, Sub-Investigator.

2010:   Sanofi-Aventis:  EFC6058- A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta, Sub-Investigator.

2010:  Sanofi-Aventis: LTS6050 – A long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg)  in patients with multiple sclerosis with relapses, Sub-Investigator.

2010:  Biogen Idec: 205MS301- A multicenter, double-blind, randomized, parallel-group monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in patients with relapsing-remitting multiple sclerosis, Sub-investigator.

A full list of research studies lead by Dr. Thomas Banas is available by request. Contact a research coordinator to request a CV.

James Stevens, MD

Past Clinical Trials & Research

2018:   F. Hoffmann-La Roche Ltd WN29922 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in patients with Early Alzheimer’s Disease. Principal Investigator. 

2018:   Balance Therapeutics BTD-001 IH202 – A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults with Idiopathic Hypersomnia. Principal Investigator.  

2018:   Jazz Pharmaceuticals 15-006 – A Double-blind, Placebo-Controlled, Randomized Withdrawal Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy, Principal Investigator.

2017:   Flamel Technologies CLFT-218-1501- A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension   (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy, Principal Investigator.   

2016:   Eli LILLY 17x-MC-LLCF – A Multicenter, Randomized, Double-blind,  Placebo-controlled, Phase 2 study for patients with mild Alzheimer’s disease dementia. Principal Investigator.           

2015:   Biogen  221AD301 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to evaluate the efficacy and safety of Aducanumab in subjects with Early Alzheimer’s Disease. Principal Investigator.

2015:  Acorda  DALF-PS-1016 – A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose-Strengths of Dalfampridine ER Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke, Sub-Investigator.           

2015:   Alexion EC-NMO-301 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Principal Investigator.

2015:   Alexion EC-NMO-302 – A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Principal Investigator.

2015:  Acorda  DZNS-EP-1025 – Phase 3 Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults with Cluster Seizures. Sub-Investigator.

2015:   Biogen 101MS413 – A Phase IV Multicenter, Open-Label study to evaluate whether A Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera (delayed-release dimethyl fumarate) treatment in MS patients, Principal Investigator.

2014:   Biogen 101MS409 – A Phase IIII Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis. Principal Investigator.

2013:   Sanofi Aventis LPS13567 – A Prospective, Single-Arm, Clinical-Setting, Study to Describe Efficacy, Tolerability and convenience of AUBAGIO Treatment Using Patient Reported Outcomes in Relapsing Multiple Sclerosis Patients. Principal Investigator.

2013:   Teva LAQ MS 305 – A multinational, multicenter, randomized, double blind, parallel group placebo-controlled study followed by an active treatment period to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquiniod in subjects with Relapsing Remitting Multiple Sclerosis. Principal Investigator. 

2013:   Opexa 2012-00 A Phase II Double-Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of Tcelna™ in Subjects with Secondary Progressive Multiple Sclerosis. Principal Investigator.           

A complete list of research studies lead by Dr. James Stevens is available by request.

Ajay Gupta, MD

Past Clinical Trials & Research

2018:   F. Hoffmann-La Roche Ltd WN29922 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in patients with Early Alzheimer’s Disease. Principal Investigator. 

2018:   Balance Therapeutics BTD-001 IH202 – A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults with Idiopathic Hypersomnia. Principal Investigator.

2018:   Jazz Pharmaceuticals 15-006 – A Double-blind, Placebo-Controlled, Randomized Withdrawal Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy, Principal Investigator.

2017:  Flamel Technologies CLFT-218-1501- A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension   (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy, Principal Investigator.   

2016:   Eli LILLY 17x-MC-LLCF – A Multicenter, Randomized, Double-blind,  Placebo-controlled, Phase 2 study for patients with mild Alzheimer’s disease dementia. Principal Investigator.          

2015:   Biogen  221AD301 – A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to evaluate the efficacy and safety of Aducanumab in subjects with Early Alzheimer’s Disease. Principal Investigator.

2015:  Acorda  DALF-PS-1016 – A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose-Strengths of Dalfampridine ER Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke, Sub-Investigator.            

2015:   Alexion EC-NMO-301 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO) Principal Investigator.

2015:   Alexion EC-NMO-302 – A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Principal Investigator.

2015:  Acorda  DZNS-EP-1025 – Phase 3 Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults with Cluster Seizures. Sub-Investigator.   

2015:  Biogen 101MS413 – A Phase IV Multicenter, Open-Label study to evaluate whether A Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera (delayed-release dimethyl fumarate) treatment in MS patients, Principal Investigator.

2014:   Biogen 101MS409 – A Phase IIII Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis. Principal Investigator.

2013:   Sanofi Aventis LPS13567 – A Prospective, Single-Arm, Clinical-Describe Efficacy, Tolerability and convenience of AUBAGIO Treatment Using Patient Reported Outcomes in Relapsing Multiple Sclerosis Patients. Principal Investigator.

A complete list of research studies lead by Dr. Ajay Gupta is available by request.

Marlene Bultemeyer, MD

Past Clinical Trials & Research

2019:  UCB Biopharma SPRL – EP0092 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy.

2018:  Eisai – E2007-G000-506 – A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients with Epilepsy. Primary Investigator

2016:  Eli LILLY 17x-MC-LLCF – A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 3 study for patients with mild Alzheimer’s disease. Sub- Investigator.

2016:  Acorda DALF PS 1016 – Phase 3 Double-Blind Placebo- Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking deficits in Post-Ischemic Stroke. Primary Investigator.

2016:  Acorda DALF PS 1029 – Phase 3 Double-Blind Placebo- Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking deficits in Post-Ischemic Stroke. Primary Investigator.

2015: Biogen – 221AD301 – A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to evaluate the efficacy and safety of Aducanumab in subjects with Early Alzheimer’s Disease. Sub-Investigator.

2015:  Alexion ECU-NMO-301 – Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-center trial to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub-Investigator.  

2015:  Alexion ECU-NMO-302 – Phase 3 Open-Label, Extension Trial of ECU-NMO-301 to evaluate the Safety and Efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub-Investigator.    

2015:  Acorda  DZNS-EP-1025 – Phase 3 Open-Label, Safety and Tolerability Study of  Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults with Cluster Seizures. Principal Investigator.

2015:  Biogen 109MS413 – A multicenter, open-label phase IV study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecifedera® (delayed-release dimethyl fumarate) treatment in multiple sclerosis patients, Sub-Investigator.  

2013:  Teva LAQ MS 305 – A multinational, multicenter, randomized, double blind,Parallel group placebo controlled study followed by an active treatment period to evaluate the efficacy, safety and tolerability of two doses of oral administration of Laquiniod in subjects with Relapsing Remitting Multiple Sclerosis. Sub-Investigator. 

2013:  Opexa 2012-00 – A phase II double-blind placebo controlled multicenter study to evaluate the efficacy and safety of Tcelna in subjects with SPMS. Sub-Investigator.

2012:  Parkview – A phase II double-blind placebo controlled multicenter study to evaluate the efficacy, safety and tolerability of PF-03049423 in subjects with Ischemic Stroke. Sub-Investigator.    

2011:  Parkview – A Placet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial, Randomized, Double-Blind, Multicenter clinical trial. Sub-Investigator.

2011:  Parkview – A phase II & III Study of Intravenous Thrombolysis and Hypothemia for Acute Treatment of Ischemic Stroke. The Intravascular Cooling in the Treatment of Stroke 2/3(ICTuS 2/3) Trial. Sub-Investigator.

A complete list of research studies lead by Dr. Marlene Bultemeyer is available by request.

Andrea Haller, MD

Past Clinical Trials & Research

2018:   Jazz Pharmaceuticals – 15-006 – A Phase III Double-blind, Placebo-controlled Randomized Withdrawal Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy, Sub-Investigator

2017:   Flamel/Avadel – CLFT218-1501 – A Phase III Double-blind, Placebo controlled to assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy, Sub-Investigator.

2016:   Duke Clinical Research Institute “Aramis” Study, Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-World Anticoagulant Management Issues and Stroke. Principal Investigator.

2016:   Techfields, Inc. – TF20023 A Phase II, Multicenter, Randomized, Double-Blind (within dose), Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study to Evaluate the Efficacy and Safety of TF0023 Spray versus Placebo in Functional Improvement of Patients with Ischemic Strokes. Principal Investigator.

2015:   Alexion EC-NMO-301 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center trial to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub-Investigator.

2015:   Alexion EC-NMO-302 – A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to evaluate the safety and efficacy of Eculizumab in patients with Relapsing Neuromyelitis Optica (NMO). Sub-Investigator.

2015:   Biogen 221AD301 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Parallel–Group Study to evaluate the efficacy and safety of Aducanumab in subjects with early Alzheimer’s Disease. Sub-Investigator.

2008:   Sapphire World Wide Carotid Stent Trial (SAPPHIRE). Neurology Consultation, Sub-Investigator.

A complete list of research studies lead by Dr. Andrea Haller is available by request.